At BRL Medicine Inc., we aim to become the world's leading Cellular & Gene pharmaceutical company in the era of new commercial civilization, with the mission of "Leading innovation with gene editing, developing breakthrough therapy and benefiting all mankind". With its independent R&D center and the "Shanghai Research Center for Gene Editing and Cell Therapy", jointly established by BRL Medicine and university, BRL Medicine has obtained more than 100 patent achievements, and initiated 19 Investigator-Initiated clinical Trials (IIT) in 20 leading hospitals in China, 6 projects having received IND approvals, with many pipeline projects have entered into IND application stage. Notably, its gene editing therapy for β-thalassemia, non-viral site-specific integrated PD1-CAR-T, and UCAR-T projects have demonstrated excellent clinical outcomes, achieving global leadership and resulting in numerous publications in top-tier journals like Nature, Cell, Nature Medicine, and Nature Biotechnology. BRL Medicine has built six technology platforms with independent intellectual property rights, including The Gene Editing Technology Innovation Platform, Hematopoietic Stem Cell Platform, The Quikin CAR-T Platform, Universal Cell Platform, Enhanced T Cell Platforms and In Vivo Gene Editing CAR-T Platform, and has a 7000 square meter GMP pilot plant and an operating team of nearly 100 people, which strongly guarantees the rapid transformation and application of innovative research. BRL Medicine continuously promotes rapid update and iteration of R&D products through patient needs and clinical feedback. BRL Medicine holds an open, shared, and win-win attitude, and works with global innovative biomedical ecological chain companies to accelerate the transformation and implementation of innovative drugs, so as to benefit global patients with genetic diseases, malignancies, and autoimmune disorders.
Dedicated to the development and translation of gene editing and cell therapy and gene therapy for genetic diseases caused by gene mutations
Nearly 100 people
Contains 10% PhD and 23.5% Master
125+
Has applied for 125 invention patents at home and abroad
Has five core technology platforms with independent intellectual property rights
Relying on its strong technical strength and scientific research team in the field of gene editing and immunology, BRL Medicine is dedicated to the development and translation of gene editing and cell therapy, as well as gene therapy for genetic diseases caused by gene mutations.
